retatrutide phase 3 results october 2025 Updates: Significant Weight Loss and Improved Complications | Ahmad Bahareth, MD posted on the topic Retatrutide Phase 3: TRIUMPH Program

Several evidence-based strategies complement the medication effects and can improve both weight loss outcomes and overall postpartum recovery

20.8% weight loss at 12 mg, and A1C down 1.5% at 12 mg (1.6% at 9 mg) from a 7.7% baseline

by Nadia B

For now we dont have that information with GLP-1 products, but we are collecting the information so we will see. But the growing use of GLP-1 drugs is also thought to be fuelling other abuses

Based on the available evidence, cagrilintide appears to have a more favorable body composition profile, though the magnitude of difference between the two compounds remains to be determined through direct comparison studies

This strategic design allows researchers to fully engage the GIP pathway for enhanced metabolic effects while minimizing the dose-limiting gastrointestinal tolerability issues common with high-dose GLP-1 agonism, making it uniquely valuable for studying synergistic incretin mechanisms